Skip to main content

Advertisement

Log in

Nonadherence as 4-day Antiretroviral Therapy Interruptions: Do Depression and Race/Ethnicity Matter as Much in the Modern Antiretroviral Therapy Era?

  • Brief Report
  • Published:
AIDS and Behavior Aims and scope Submit manuscript

Abstract

HIV + White, Latino, and African Americans (N = 1131) completed a survey advertised on social media to re-examine the effect of depressive symptoms (via the Patient Health Questionnaire; PHQ-9) and race/ethnicity on antiretroviral therapy nonadherence (defined as past 3-month, 4-day treatment interruption). An adjusted logistic regression showed a 15 % increase in odds for a treatment interruption per 1-unit increase on the PHQ-9. The effect of depressive symptoms on nonadherence was greater for Latinos (OR = 1.80, p < 0.05), but not for African Americans, compared to Whites. The benefits of modern ART (e.g., simpler, forgiving to minor lapses) may not circumvent the effect of depressive symptomatology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Oh DL, Sarafian F, Silvestre A, et al. Evaluation of adherence and factors affecting adherence to combination antiretroviral therapy among White, Hispanic, and Black men in the MACS Cohort. J Acquir Immune Defic Syndr. 2009;52:290–300.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Simoni JM, Huh D, Wilson IB, et al. Racial/ethnic disparities in ART adherence in the United States: findings from the MACH14 Study. J Acquir Immune Defic Syndr. 2012;60:466–72.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Wagner GJ, Goggin K, Remien RH, et al. A closer look at depression and its relationship to HIV antiretroviral adherence. Ann Behav Med. 2011;42:352–60.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58:181–7.

    PubMed  Google Scholar 

  5. Nachega JB, Mugavero MJ, Zeier M, Vitoria M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence. 2011;5:357–67.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Parienti J-J, Paterson DL. Number of missed doses: why 1 × 7 does not make 7 × 1? AIDS. 2012;26:1437–40.

    Article  PubMed  Google Scholar 

  7. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40:158–63.

    Article  CAS  PubMed  Google Scholar 

  8. Bangsberg DR. Less than 95 % adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939–41.

    Article  CAS  PubMed  Google Scholar 

  9. Nelson M, Girard PM, Demasi R, et al. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. J Antimicrob Chemother. 2010;65:1505–9.

    Article  CAS  PubMed  Google Scholar 

  10. Genberg BL, Wilson IB, Bangsberg DR, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26:1415–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Parienti J-J, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS ONE. 2008;3:e2783.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Parienti J, Ragland K, Lucht F, et al. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis. 2010;15:1192–7.

    Article  Google Scholar 

  13. Yuan P, Bare MG, Johnson MO, Saberi P. Using online social media for recruitment of human immunodeficiency virus-positive participants: a cross-sectional survey. J Med Internet Res. 2014;16:e117.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kalichman SC, Rompa D, Cage M. Reliability and validity of self-reported CD4 lymphocyte count and viral load test results in people living with HIV/AIDS. Int J STD AIDS. 2000;11:579–85.

    Article  CAS  PubMed  Google Scholar 

  15. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption—II. Addiction. 1993;88:791–804.

    Article  CAS  PubMed  Google Scholar 

  16. Carrico AW, Johnson MO, Morin SF, et al. Stimulant use is associated with immune activation and depleted tryptophan among HIV-positive persons on anti-retroviral therapy. Brain Behav Immun. 2008;22:1257–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kalichman SC, Rompa D, Cage M. Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIV-AIDS. J Nerv Ment Dis. 2000;188:662–70.

    Article  CAS  PubMed  Google Scholar 

  19. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta- analysis. Clin Infect Dis. 2009;48:484–8.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Dawson JF. Moderation in management research: what, why, when and how. J Bus Psychol. 2014;29:1–19.

    Article  Google Scholar 

  21. Dawson JF. Two-way interactions. interpreting interaction effects. http://www.jeremydawson.co.uk/slopes.htm. Accessed 9 Oct 2014.

  22. Carrico AW, Riley ED, Johnson MO, et al. Psychiatric risk factors for HIV disease progression: the role of inconsistent patterns of antiretroviral therapy utilization. J Acquir Immune Defic Syndr. 2011;56:146–50.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Alegría M, Mulvaney-Day N, Woo M, Torres M, Gao S, Oddo V. Correlates of past-year mental health service use among Latinos: results from the National Latino and Asian American Study. Am J Public Health. 2007;97:76–83.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Compton S, Haack S, Phillips CR. Identification of barriers to medication adherence in a Latino population. Res Soc Adm Pharm. 2010;6:365–71.

    Article  Google Scholar 

  25. Dang BN, Giordano TP, Kim JH. Sociocultural and structural barriers to care among undocumented Latino immigrants with HIV Infection. J Immigr Minor Health. 2012;14:124–31.

    Article  PubMed  Google Scholar 

  26. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227–45.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We are grateful to the participants in this study. The first author completed the manuscript with postdoctoral support by Grant T32 MH19105 and support to the second author was provided by K23 MH097649, both from the National Institute of Mental Health (NIMH) of the U.S. Public Health Service. Support to the third author was provided by K24 DA037034 and R01 MH102198 from the National Institute of Drug Abuse and the NIMH.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John A. Sauceda.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sauceda, J.A., Johnson, M.O. & Saberi, P. Nonadherence as 4-day Antiretroviral Therapy Interruptions: Do Depression and Race/Ethnicity Matter as Much in the Modern Antiretroviral Therapy Era?. AIDS Behav 20, 2624–2628 (2016). https://doi.org/10.1007/s10461-015-1283-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10461-015-1283-8

Keywords

Navigation